Who makes LY2140023 Test-Medium?

LY2140023 Test-Medium is developed by Denovo Biopharma LLC.

What development phase is LY2140023 Test-Medium in?

LY2140023 Test-Medium is in Phase 1.

Last reviewed 2026-04-19 · How we verify

LY2140023 Test-Medium

Denovo Biopharma LLC · Phase 1 active Small molecule

At a glance

Generic name	LY2140023 Test-Medium
Also known as	LY2140023 Monohydrate (Test - Medium)
Sponsor	Denovo Biopharma LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of LY2140023 in Healthy Males and Females (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LY2140023 Test-Medium CI brief — competitive landscape report
LY2140023 Test-Medium updates RSS · CI watch RSS
Denovo Biopharma LLC portfolio CI